Leerink Partnrs Analysts Lift Earnings Estimates for SPRB

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Leerink Partnrs increased their Q2 2025 earnings per share estimates for Spruce Biosciences in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.24) per share for the quarter, up from their previous estimate of ($0.26). The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for Spruce Biosciences’ Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.68) EPS and FY2026 earnings at ($0.41) EPS.

Separately, Royal Bank of Canada reduced their price objective on Spruce Biosciences from $1.50 to $0.50 and set a “sector perform” rating for the company in a report on Wednesday, April 16th. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, Spruce Biosciences presently has a consensus rating of “Hold” and an average price target of $2.17.

Spruce Biosciences Trading Down 0.5 %

Shares of SPRB stock opened at $0.07 on Friday. The company has a quick ratio of 5.36, a current ratio of 5.36 and a debt-to-equity ratio of 0.01. The firm has a market cap of $3.06 million, a P/E ratio of -0.08 and a beta of 2.49. The company has a 50 day moving average of $0.24 and a 200-day moving average of $0.37. Spruce Biosciences has a 12-month low of $0.06 and a 12-month high of $0.87.

Spruce Biosciences (NASDAQ:SPRB) last posted its quarterly earnings results on Tuesday, April 15th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.37). The company had revenue of $0.55 million for the quarter, compared to the consensus estimate of $0.50 million. Spruce Biosciences had a negative net margin of 555.23% and a negative return on equity of 62.10%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Spruce Biosciences stock. Boothbay Fund Management LLC purchased a new stake in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 288,800 shares of the company’s stock, valued at approximately $121,000. Boothbay Fund Management LLC owned about 0.70% of Spruce Biosciences at the end of the most recent quarter. 91.71% of the stock is owned by institutional investors.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.